Compare CPRI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRI | KOD |
|---|---|---|
| Founded | 1981 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2011 | 2018 |
| Metric | CPRI | KOD |
|---|---|---|
| Price | $18.27 | $33.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $26.62 | ★ $35.43 |
| AVG Volume (30 Days) | ★ 3.2M | 551.3K |
| Earning Date | 05-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,474,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $16.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.49 | $3.43 |
| 52 Week High | $28.27 | $47.84 |
| Indicator | CPRI | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 38.27 |
| Support Level | $16.82 | $32.93 |
| Resistance Level | $22.24 | $46.72 |
| Average True Range (ATR) | 0.89 | 2.28 |
| MACD | 0.11 | -0.34 |
| Stochastic Oscillator | 41.86 | 14.38 |
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.